AlphaMadera's AlphaVal page computes American Healthcare REIT, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag AHR as undervalued, fairly valued, or overvalued.

What is American Healthcare REIT, Inc.'s fair value?

Fair value for AHR is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value AHR?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from AHR's most recent reported fundamentals.

AHR - American Healthcare REIT, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $58.57 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Real Estate Investment Trust 85% confidence

Primary model: P/FFO × Healthcare REIT Multiple

Valuation Signal Overvalued Strong

Trading 75.9% above fair value

Current Price $57.16

Bear Case $25.78 54.9% downside ($25.78 - $57.16) / $57.16 = -54.9% $1.24 FFO × 18x

Fair Value $32.50 43.1% downside ($32.50 - $57.16) / $57.16 = -43.1% $1.24 FFO × 23x

Bull Case $39.22 31.4% downside ($39.22 - $57.16) / $57.16 = -31.4% $1.24 FFO × 29x

Adjust Assumptions

P/FFO Multiple

23.4x

FFO per Share

1.24$

Key Value Driver

FFO/share ($1.24) × healthcare P/FFO multiple

Implied Market Multiple 45.9x

Plain-Language Summary

Our base-case estimate uses P/FFO × Healthcare REIT Multiple. We then blend that result with the average analyst price target of $58.57 from 12 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $32.50 per share.

Warnings

⚠ Standard profit figures are misleading for real estate companies — large non-cash accounting charges make profits look artificially low. Dividend yield and funds from operations are better measures.

ℹ The 1.7% yield is low for a real estate company — investors are paying up because they expect above-average growth.

ℹ Dividend-based valuation: $18.64 (28% below our primary estimate). Large gaps suggest the dividend may not fully reflect the company's value.

ℹ Wall Street's average price target is $58.57 (from 12 analysts). Our estimate is 56% below the consensus -- consider that gap carefully.

Key Risks

P/E and EV/EBITDA are structurally wrong for REITs — use P/FFO and NAV
Interest rate sensitivity: REIT multiples compress when rates rise
FFO approximation (NI + D&A) may include gains on property sales — verify